• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

Insulin Therapy: Dosing Considerations, Injectable Options, and Tailoring for Glucose Control

Opinion
Video

Leading experts in geriatric diabetes care explore comprehensive aspects of insulin therapy, including dosing strategies, available injectable options, and methods for tailoring glucose control in elderly patients.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
t New Guidelines Recommend Preconception Screening in Diabetes, Universal Testing for Primary Aldosteronism

New Guidelines Recommend Preconception Screening in Diabetes, Universal Testing for Primary Aldosteronism

Grace Halsey
July 16th 2025
Article

ENDO 2025: The publications reflect growing consensus that integration of endocrine screening into standard clinical workflows is essential for early risk detection and long-term disease prevention.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Novel GLP-1/GLP-2 Agent Reduces Body Weight by Up to 8.3% in Phase 1b Obesity Trial

Novel GLP-1/GLP-2 Agent Reduces Body Weight by Up to 8.3% in Phase 1b Obesity Trial

Sydney Jennings
July 7th 2025
Article

ADA 2025: Dapiglutide showed promising safety and weight loss results in a phase 1b trial, targeting obesity and inflammation with once-weekly dosing.

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Sydney Jennings
July 22nd 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

Mifepristone Reduced HbA1c, Body Weight in Adults with Hypercortisolism and Inadequately Controlled T2D: CATALYST Trial Treatment Phase

Mifepristone Reduced HbA1c, Body Weight in Adults with Hypercortisolism and Inadequately Controlled T2D: CATALYST Trial Treatment Phase

Sydney Jennings
June 24th 2025
Article

ADA 2025: Mifepristone lowered HbA1c levels by about 1.5% over 24 weeks vs placebo among participants with hypercortisolism and inadequately controlled T2D.

Orforglipron, an Investigational Oral GLP-1, Cuts HbA1c and Body Weight in People With T2D

Orforglipron, an Investigational Oral GLP-1, Cuts HbA1c and Body Weight in People With T2D

Sydney Jennings
June 23rd 2025
Article

ADA 2025: Orforglipron lowered HbA1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as 4 weeks, in a phase 3 trial.

© 2025 MJH Life Sciences

All rights reserved.